Mumbai, November 29, 2017: Pharma Major, Zydus Cadila said that it has received the final approval from the United States Food and Drug Administration (USFDA) to market Topiramate Extended-Release Capsules in the strengths of 25 mg, 50 mg, and 100 mg.
The drug is indicated for the treatment of seizures and migraine headaches, company said in afiling with BSE.
It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
The group now has more than 170 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.
United News of India
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…